| SKŘIČKOVÁ, Jana, Lenka BABIČKOVÁ, Jana KAPLANOVÁ, Olga KUBOVÁ, Ivana PALKOVA a Marcela TOMÍŠKOVÁ. Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer. In Woorkbook of Iressa Clinical Experience Meeting. Madrid, Spain: AstraZeneca, 2003, s. 58. |
Další formáty:
BibTeX
LaTeX
RIS
@inproceedings{488054,
author = {Skřičková, Jana and Babičková, Lenka and Kaplanová, Jana and Kubová, Olga and Palkova, Ivana and Tomíšková, Marcela},
address = {Madrid, Spain},
booktitle = {Woorkbook of Iressa Clinical Experience Meeting},
keywords = {non-small-cell lung cancer; gefitinib treatment; survival rate},
language = {eng},
location = {Madrid, Spain},
pages = {58-58},
publisher = {AstraZeneca},
title = {Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer},
year = {2003}
}
TY - JOUR
ID - 488054
AU - Skřičková, Jana - Babičková, Lenka - Kaplanová, Jana - Kubová, Olga - Palkova, Ivana - Tomíšková, Marcela
PY - 2003
TI - Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer
PB - AstraZeneca
CY - Madrid, Spain
KW - non-small-cell lung cancer
KW - gefitinib treatment
KW - survival rate
N2 - Forty-five patients with non-small-cell lung cancer underwent treatment with gefitinib; 51% of them had prior radiotherapy. Treatment duration was 1 to 14 months (median, 3 months). Diseased progressed in 18 patients within 3 months, but stabilised in 27 patients for longer than 3 months. Disease-related symptoms were generally milder after gefitinib treatment.
ER -
SKŘIČKOVÁ, Jana, Lenka BABIČKOVÁ, Jana KAPLANOVÁ, Olga KUBOVÁ, Ivana PALKOVA a Marcela TOMÍŠKOVÁ. Results of treatment with gefitinib (''Iressa'',ZD1839) in 45 patients with advanced non-small-cell lung cancer. In \textit{Woorkbook of Iressa Clinical Experience Meeting}. Madrid, Spain: AstraZeneca, 2003, s.~58.
|
